TRISHA JOBMAN: Open Payments
NPI 1407283252 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,192 in 131 payments from 15 companies in 2025. Trend: 2023 $2,098 · 2024 $2,346 · 2025 $2,192
Food & beverage: $2,192
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $363 |
| Janssen Pharmaceuticals, Inc | 22 | $329 |
| Otsuka America Pharmaceutical, Inc. | 15 | $268 |
| Lundbeck LLC | 21 | $265 |
| ABBVIE INC. | 12 | $227 |
| Teva Pharmaceuticals USA, Inc. | 12 | $177 |
| Alkermes, Inc. | 10 | $163 |
| Collegium Pharmaceutical, Inc. | 5 | $100 |
| E.R. Squibb & Sons, L.L.C. | 5 | $92 |
| Axsome Therapeutics, Inc. | 4 | $70 |
Products named: REXULTI, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, ARISTADA, ABILIFY MAINTENA, AUSTEDO XR, Jornay PM.
Industry payments across NE — which companies pay providers there.
